Use of cinnamyl aldehyde in preparation of drugs for improving iron deficiency anemia and adverse pregnancy outcomes of pregnant women during pregnancy

Abstract

The application discloses application of cinnamyl aldehyde in preparation of a medicine for improving iron deficiency anemia and adverse pregnancy outcomes of pregnant women during pregnancy, and after treatment with the cinnamyl aldehyde, anemia symptoms of the pregnant women caused by iron deficiency during pregnancy can be significantly relieved, and adverse pregnancy outcomes caused by iron deficiency anemia can also be relieved, and the specific performance is relieving fetal growth restriction, thereby providing a new medicine and treatment selection for treating iron deficiency anemia and improving adverse pregnancy outcomes of the pregnant women during pregnancy.

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, specifically to the application of cinnamaldehyde in the preparation of drugs to improve iron deficiency anemia and adverse pregnancy outcomes in pregnant women. Background Technology

[0002] Clinically, iron deficiency anemia during pregnancy is the most common type of anemia, most frequently occurring in the second and third trimesters. During pregnancy, a woman's iron requirements gradually increase. Therefore, in the later stages of pregnancy, increased requirements, poor absorption, or a lack of dietary sources can lead to insufficient iron intake, resulting in iron deficiency anemia. Iron deficiency anemia in pregnant women primarily affects fetal development, including fetal growth restriction (FGR), intrauterine fetal death, or premature birth. During pregnancy, the nutrients required for fetal development in utero come from the mother. These nutrients are transported to the placenta via blood circulation and further to the fetus through the umbilical cord connected to the placenta.

[0003] The inventors' research group collected blood routine test results and delivery information (newborn growth and development indicators on the day of birth) of 250 pregnant women aged 20-40 years in late pregnancy from January 2023 to December 2024 at the Third Affiliated Hospital of Southern Medical University, and conducted relevant clinical regression analysis and statistical analysis. Clinical regression analysis showed that approximately 37.04% of the 250 pregnant women aged 20-40 years had iron deficiency anemia. Figure 1 (This proportion excludes anemia caused by thalassemia). Based on clinical data, the 250 pregnant women were then divided into healthy pregnant women (150 cases) and pregnant women with iron deficiency anemia (100 cases). Statistical analysis showed that, compared with healthy pregnant women, pregnant women with iron deficiency anemia had abnormal blood routine results, specifically significantly reduced total red blood cell count, hemoglobin concentration, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. Furthermore, pregnant women with iron deficiency anemia experienced adverse pregnancy outcomes (fetal growth restriction), specifically reduced biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC), and femur length (FL).

[0004] In addition, elderly pregnant women (pregnant women aged 35 or above) are more likely to have iron deficiency anemia due to the beginning of the decline in body conditions than normal age pregnant women. At present, iron deficiency anemia of pregnant women during pregnancy is generally treated by supplementing iron agents in clinic, such as ferrous sulfate or ferrous succinate, ferrous fumarate and citric acid iron ammine. However, these iron agents have different degrees of irritation to the gastrointestinal tract, causing some adverse symptoms such as upper abdominal discomfort, diarrhea, constipation and the like in pregnant women.

[0005] Cinnamon is the dried bark of Cinnamomum cassia Presl, which has the effects of tonifying fire and assisting yang, guiding fire back to the origin, dispelling cold and relieving pain, and warming the channels and vessels. Cinnamyl aldehyde is a natural organic substance extracted from the bark of Cinnamomum cassia, which has various biological activities, can regulate the concentration in the body through the intestinal mucosal system, is not affected by gastric acid in the digestive tract, is not destroyed when taken orally, and does not increase the intestinal burden of pregnant women, and has a high biological safety factor. Current studies have confirmed that cinnamyl aldehyde has important effects in antibacterial, anti-inflammatory, anti-ulcer, antioxidant, anti-tumor and fat decomposition. In addition, cinnamyl aldehyde can improve insulin sensitivity and help reduce blood sugar levels, so it has certain clinical significance for pregnant women with gestational diabetes. Cinnamyl aldehyde contained in cinnamon has the effect of promoting blood circulation, but it is still unclear that cinnamyl aldehyde, as one of the important medical raw materials, can improve and relieve iron deficiency anemia in pregnant women during pregnancy.

[0006] At present, there is still a lack of drugs without side effects and affecting the health of mothers and infants for improving iron deficiency anemia in pregnant women during pregnancy in clinic. More importantly, the treatment research on adverse pregnancy outcomes caused by iron deficiency anemia in pregnant women during pregnancy is still in the initial stage. Therefore, it is of great significance to develop a drug capable of improving iron deficiency anemia in pregnant women during pregnancy and improving adverse pregnancy outcomes. SUMMARY

[0007] In order to overcome the above-mentioned defects and shortcomings in the prior art, the application provides the application of cinnamyl aldehyde in the preparation of a drug for improving iron deficiency anemia and adverse pregnancy outcomes in pregnant women during pregnancy.

[0008] The first object of the application is to provide the application of cinnamyl aldehyde in the preparation of a drug for improving anemia in pregnant women.

[0009] The second object of the application is to provide the application of cinnamyl aldehyde in the preparation of a drug for improving adverse pregnancy outcomes in pregnant women.

[0010] The third object of the application is to provide the application of cinnamyl aldehyde in the preparation of a drug for relieving fetal growth restriction.

[0011] Therefore, the application claims the following contents:

[0012] The application of cinnamyl aldehyde in the preparation of a drug for improving anemia in pregnant women.

[0013] Preferably, the anemia is iron deficiency anemia.

[0014] Use of cinnamyl aldehyde in the preparation of a drug for improving adverse pregnancy outcomes of pregnant women.

[0015] Preferably, the pregnant woman is a pregnant woman with iron deficiency anemia during pregnancy.

[0016] Preferably, the adverse pregnancy outcome of the pregnant woman is an adverse pregnancy outcome caused by iron deficiency anemia of the pregnant woman.

[0017] Further preferably, the adverse pregnancy outcome of the pregnant woman is an adverse pregnancy outcome caused by iron deficiency anemia of the pregnant woman.

[0018] Preferably, the adverse pregnancy outcome is an adverse pregnancy outcome of a fetus.

[0019] Further preferably, the adverse pregnancy outcome of the fetus is fetal growth restriction.

[0020] Still further preferably, the fetal growth restriction is fetal weight loss, fetal length shortening, and / or fetal growth restriction caused by placental weight loss.

[0021] Use of cinnamyl aldehyde in the preparation of a drug for relieving fetal growth restriction.

[0022] Preferably, the fetal growth restriction is fetal weight loss, fetal length shortening, and / or fetal growth restriction caused by placental weight loss.

[0023] Compared with the prior art, the present application has the following beneficial effects:

[0024] The application discloses use of cinnamyl aldehyde in the preparation of a drug for improving adverse pregnancy outcomes of pregnant women with iron deficiency anemia during pregnancy. After treatment with cinnamyl aldehyde, the anemia symptoms caused by iron deficiency of the pregnant woman during pregnancy can be significantly relieved. Meanwhile, the adverse pregnancy outcomes caused by iron deficiency anemia of the pregnant woman can be relieved, specifically, fetal growth restriction can be relieved, thereby providing a new drug and treatment option for treating iron deficiency anemia of the pregnant woman during pregnancy and adverse pregnancy outcomes. BRIEF DESCRIPTION OF DRAWINGS

[0025] Figure 1 Clinical data statistics results of healthy pregnant women and iron deficiency anemia pregnant women.

[0026] Figure 2 A schematic diagram of experimental design of a mouse model.

[0027] Figure 3 Anemia index of pregnant rats at 18.5 days of pregnancy (E18.5) in a normal group (healthy pregnancy group), an iron deficiency group (iron deficiency group), and an experimental group (iron deficiency + cinnamyl aldehyde treatment).

[0028] Figure 4Representative images of fetal and placental development in normal group (healthy pregnancy group), iron deficiency group (iron deficiency group) and experimental group (iron deficiency + cinnamyl aldehyde treatment group).

[0029] Figure 5 Fetal growth and development indicators in normal group (healthy pregnancy group), iron deficiency group (iron deficiency group) and experimental group (iron deficiency + cinnamyl aldehyde treatment group). DETAILED DESCRIPTION

[0030] The present application will be further described in conjunction with specific examples, but the examples do not limit the present application in any form. Unless otherwise specified, the reagents, methods and equipment used in the present application are conventional reagents, methods and equipment in the technical field.

[0031] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0032] Example 1 Construction of a model of iron deficiency anemia in pregnant rats during pregnancy

[0033] The experimental design flow chart is shown in Figure 2 The mice were divided into normal group, iron deficiency group and experimental group:

[0034] Normal group (Normal): 8-12 week old female mice were found on the day of vaginal plug, recorded as E0.5, and fed with breeding feed (source: Guangdong Medical Laboratory Animal Center; iron content: 200 ppm) from E0.5, free intake of mouse feed, and drank double distilled water without cinnamyl aldehyde throughout pregnancy, and collected the blood of pregnant mice at E18.5 to detect anemia indicators. Subsequently, the pregnant mice were euthanized and the fetuses and placentas were stripped.

[0035] Iron deficiency group (Low-iron diet): 8-12 week old female mice were found on the day of vaginal plug, recorded as E0.5, and fed with low-iron feed (source: Guangdong Medical Laboratory Animal Center; item number: AIN-93G-0Fe iron-deficient purified mouse feed; iron content: 2 ppm) from E0.5, free intake of mouse feed, and drank double distilled water without cinnamyl aldehyde throughout pregnancy, and collected the blood of pregnant mice at E18.5 to detect anemia indicators. Subsequently, the pregnant mice were euthanized and the fetuses and placentas were stripped.

[0036] The experimental group (Cinnamaldehyde): 8-12 weeks of female mice found on the day of vaginal plug was recorded as E0.5, and E0.5 began to feed low-iron feed (source: Guangdong Medical Experimental Animal Center; item number: AIN-93G-0Fe iron-deficient purified mouse feed; iron content: 2 ppm; literature recommended pregnant mouse gestational period feed iron content: 200 ppm), free intake of mouse feed, from E13.5 start to drink double distilled water containing cinnamaldehyde (Cinnamaldehyde; source: Chengdu Efa Biotechnology Co., Ltd.; item number: AB2387-0020; CAS number: 104-55-2) every day, the dose of cinnamaldehyde was 20 mg / kg / day, and the blood of pregnant mice was collected at E18.5 to detect anemia indicators. Then the pregnant mice were euthanized and the fetuses and placentas were stripped.

[0037] Example 2 Effect of cinnamaldehyde on iron deficiency anemia in pregnant mice during pregnancy

[0038] I. Experimental method

[0039] The anemia indicators of pregnant mice in the normal group, the iron deficiency group and the experimental group in Example 1 at E18.5 were detected, including the total amount of red blood cells (RBC), hemoglobin concentration (Hb), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC).

[0040] II. Experimental results

[0041] The results are shown in Table 1. Figure 3 As shown in Table 1, the analysis results showed that in the blood of the normal group of pregnant mice, the total amount of RBC was 8.0-10.2 x 10 12 / L, the Hb concentration was 125-150 g / L, the HCT ratio was 0.4-0.45, the MCV was 50-58 fL, the MCH was 325-335 pg, and the MCHC was 15.8-17.5 g / L.

[0042] Compared with the normal group, the blood indicators of the iron deficiency group of pregnant mice were abnormal, showing decreased RBC, Hb, HCT, MCV, MCH and MCHC, wherein the total amount of RBC was 6.0-6.2 x 10 12 / L, the Hb concentration was 90-108 g / L, the HCT ratio was 0.28-0.35, the MCV was 44-48 fL, the MCH was 280-315 pg, and the MCHC was 14.5-15.5 g / L.

[0043] Compared with the iron deficiency group, the blood indexes of the experimental group of pregnant mice recovered, specifically, RBC, Hb, HCT, MCV, MCH and MCHC increased, wherein the total amount of RBC was 8.0-9.8 x 10 12 / L, the concentration of Hb was 120-148 g / L, the ratio of HCT was 0.42-0.44, MCV was 47-54 fL, MCH was 320-340 pg, MCHC was 15.5-17.2 g / L, and basically recovered to the level of the normal group.

[0044] Example 3 Influence of cinnamyl aldehyde on fetal growth and development

[0045] I. Experimental method

[0046] For the normal group, the iron deficiency group and the experimental group of pregnant mice in Example 1, the pregnant mice were euthanized and the fetuses were stripped at E18.5, and the fetal growth and development indexes were detected: fetal weight, placental weight, fetal length and fetal tail length.

[0047] II. Experimental results

[0048] The results are shown in Figure 4 and Figure 5 . The analysis results show that the fetal weight of the normal group of pregnant mice is 0.852-0.122 g, the placental weight is 0.085-0.123 g, the fetal length is 19.8-23.2 mm, and the fetal tail length is 10.0-13.2 mm.

[0049] Compared with the normal group, the fetal growth restriction occurred in the iron deficiency group of pregnant mice, specifically, the fetal weight, placental weight, body length and tail length decreased, wherein the fetal weight was 0.683-1.002 g, the placental weight was 0.075-0.118 g, the fetal length was 17.0-22.5 mm, and the fetal tail length was 8.30-11.7 mm.

[0050] Compared with the iron deficiency group, the fetal growth and development of the experimental group of pregnant mice recovered, specifically, the fetal weight, placental weight, body length and tail length increased, wherein the fetal weight was 0.950-1.189 g, the placental weight was 0.092-0.121 g, the fetal length was 21.5-23.3 mm, and the fetal tail length was 10.2-12.8 mm, basically recovered to the level of the normal group.

[0051] The above examples are the preferred embodiments of the present application, but the embodiments of the present application are not limited to the above examples, any changes, modifications, substitutions, combinations, simplifications made without departing from the spirit and principles of the present application should be equivalent replacement methods, and are all included in the protection scope of the present application.

Claims

1. The use of cinnamyl aldehyde as the sole active ingredient in the preparation of a medicament for improving anaemia in pregnant women.

2. Use according to claim 1, characterized in that, The anaemia is iron deficiency anaemia.

Images